T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer
January 07 2021 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the
rapid detection of sepsis-causing pathogens, today announced that
its Board of Directors has appointed Aparna Ahuja, MD, as Chief
Medical Officer (CMO), effective immediately.
In her new role, Dr. Ahuja will act as the company’s key medical
spokesperson providing leadership and strategic direction for all
medical, clinical and scientific affairs activities for T2
Biosystems.
“I am excited to be joining the T2 Biosystems leadership team at
this critical time when high-quality rapid diagnostics – especially
for sepsis – are growing in importance as we continue to face
mounting global health challenges, like managing antimicrobial
resistance, rising health care expenses, secondary and
co-infections associated with the COVID-19 virus,” said Dr.
Ahuja.
Dr. Ahuja possesses extensive global experience in Laboratory
Medicine and in the medical device and diagnostics industry. Most
recently, she served as Worldwide Vice President, Medical Affairs
at Becton Dickinson (NYSE:BDX), a leading global medical technology
company. Prior to Becton Dickinson, Dr. Ahuja held a variety of
roles in clinical practice, research and academia. She is an active
member of the American Association of Clinical Chemistry (AACC),
College of American Pathologists (CAP), American Society of
Microbiology (ASM), European Federation of Clinical Chemistry and
Laboratory Medicine (EFLM), and serves as President of AACC New
Jersey section and Vice Chairholder of CLSI Expert Panel.
“I am confident that Aparna’s extensive professional experience
and passion for improving patient care through diagnostic
technology will help to increase awareness and foster adoption of
our technology,” said John Sperzel, President and CEO at T2
Biosystems. “She has dedicated the entirety of her career to
continuously improving diagnostic and testing capabilities, as well
as patient outcomes, which is well-aligned with our mission and our
focus on the rapid detection of sepsis-causing pathogens.”
T2 Biosystems is the Company behind the FDA-cleared T2Bacteria®
Panel and T2Candida® Panel. These panels are the only FDA-cleared
assays for the detection of sepsis-causing bacterial and fungal
pathogens directly from whole blood in three to five hours, without
the need to wait days for blood culture results. By providing
quicker results, the panels enable clinicians to target therapy
faster for their patients suspected of sepsis, often before the
second dose of antimicrobial is administered, leading to better
patient outcomes, improved antimicrobial stewardship, and
reductions in length of stay in the hospital.
Last year, the Company received U.S. Food and Drug
Administration (FDA) Emergency Use Authorization (EUA) for its
COVID-19 molecular diagnostic test, the T2SARS-CoV-2™ Panel.
The panel detects SARS-CoV-2, the virus responsible for COVID-19
infections, and provides results in under two hours utilizing a
nasopharyngeal swab sample.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2ResistanceTM Panel, and
the T2SARS-CoV-2™ Panel and are powered by the proprietary T2
Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active
pipeline of future products, including the T2CaurisTM Panel, and
T2Lyme TM Panel, as well as additional products for the detection
of bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding the ability of
the Chief Medical Officer to impact on sepsis management and the
adoption of T2 Biosystems’ products, as well as statements that
include the words “expect,” “intend,” “plan”, “believe”, “project”,
“forecast”, “estimate,” “may,” “should,” “anticipate,” and similar
statements of a future or forward looking nature. These
forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2019, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 16, 2020, and
other filings the Company makes with the SEC from time to
time. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements
should not be relied upon as representing the Company's views as of
any date subsequent to the date of this press release.
Media Contact:Gina Kent, Vault
Communicationsgkent@vaultcommunications.com 610-455-2763
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024